SUSMED has completed a pivotal clinical trial of DTx for Insomnia and has achieved primary endpoint.
The clinical trial was a randomized double-blind study, and subjects were insomnia patients.Our DTx could significantly improve Athen Insomnia Scale, which assess insomnia disease severity, comparing with sham app.
We are going to file market authorization approval based on the result and will publish a paper about the details of trial protocol, results and so on.